AI-generated summary
Researchers compared a 607-nm prototype pulsed dye laser with a commercial 595-nm laser for benign pigmented skin lesions in 10 patients, treated randomly on each side. The authors report similar average improvement (41.2% vs 40%), with less patient discomfort during 607-nm treatment, and describe the 607-nm laser as safe and at least as effective. The small sample and pilot design limit the strength of these conclusions.
- Participants
- 10
- Who or what was studied
- 10 patients with benign epidermal pigmented lesions
- Wavelengths
- 607, 595 nm
- Limits stated in the abstract
- Small pilot study of only 10 patients, with the 607-nm laser still a study prototype.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Wavelength, Pilot study, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.